Citius Pharmaceuticals, Inc.(CTXR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.1M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CTXR Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Citius Pharmaceuticals, Inc. (CTXR), a Healthcare sector company. CTXR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.1m in revenue. Based on the latest XBRL financial filings (Q2 2026), Citius Pharmaceuticals, Inc. reports quarterly revenue of $1.7M, net income of $-28.1M, free cash flow of $-1.3M. Top institutional holders of CTXR by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. CTXR trades on the Nasdaq exchange and files with the SEC under CIK 1506251. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTXR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Citius Pharmaceuticals, Inc. directly from SEC EDGAR. Citius Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 23 and 26 since 2022, currently 25.6 — a stable long-term trajectory across 9 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.7M
Net Income
Q2 2026
$-28.1M
Free Cash Flow
Q2 2026
$-1.3M
ROIC
Q2 2026
-52.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
Operating Income
-4.9% YoYEPS (Diluted)
+39.3% YoYTotal Assets
+26.4% YoYOp. Cash Flow
+8.6% YoY| Metric | FY 2025 | FY 2023 | FY 2021 | FY 2020 | FY 2019 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $90.0K +0.0% | $90.0K +0.0% | $90.0K +80.0% | $50.0K |
| Net Income | — | $-32.5M -41.2% | $-23.1M -31.4% | $-17.5M -12.8% | $-15.6M -49.9% | $-10.4M |
| Operating Income | $-38.5M -4.9% | $-36.7M -56.1% | $-23.5M -32.9% | $-17.7M -13.5% | $-15.6M -56.2% | $-10.0M |
| EPS (Diluted) | $-3.38 +39.3% | $-5.57 -2321.7% | $-0.23 | — | — | — |
| Total Assets | $130.9M +26.4% | $103.6M -27.3% | $142.4M +225.4% | $43.8M +19.1% | $36.7M +50.5% | $24.4M |
| Operating Cash Flow | $-26.6M +8.6% | $-29.1M -19.8% | $-24.3M -43.2% | $-16.9M -36.1% | $-12.4M -56.0% | $-8.0M |
Get alerted when CTXR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Citius Pharmaceuticals, Inc. including:
Top Institutional Holders of CTXR
GEODE CAPITAL MANAGEMENT, LLC
$221.6K246,158 shVANGUARD CAPITAL MANAGEMENT LLC
$151.0K167,738 shVANGUARD FIDUCIARY TRUST CO
$70.0K77,755 shBlackRock, Inc.
$62.9K69,851 shGROUP ONE TRADING, L.P.
$57.9K64,300 shAsset Advisory Group, Inc.
$53.1K59,011 shUBS Group AG
$49.5K55,025 shNORTHERN TRUST CORP
$39.6K43,974 shSIMPLEX TRADING, LLC
$38.3K42,500 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$33.2K36,838 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $221.6K | 246,158 |
| VANGUARD CAPITAL MANAGEMENT LLC | $151.0K | 167,738 |
| VANGUARD FIDUCIARY TRUST CO | $70.0K | 77,755 |
| BlackRock, Inc. | $62.9K | 69,851 |
| GROUP ONE TRADING, L.P. | $57.9K | 64,300 |
| Asset Advisory Group, Inc. | $53.1K | 59,011 |
| UBS Group AG | $49.5K | 55,025 |
| NORTHERN TRUST CORP | $39.6K | 43,974 |
| SIMPLEX TRADING, LLC | $38.3K | 42,500 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $33.2K | 36,838 |
More Healthcare Companies
View all Healthcare →Put CTXR on your watchlist
Track score changes the day Citius Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CTXR a good stock to buy?
13F Pro's AI-powered analysis of Citius Pharmaceuticals, Inc. (CTXR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CTXR are available on the CTXR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CTXR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CTXR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Citius Pharmaceuticals, Inc.'s investment landscape.